Department of Communication Disorders, University of Massachusetts Amherst.
Department of Speech, Language, and Hearing Sciences, Purdue University, West Lafayette, IN.
J Speech Lang Hear Res. 2022 Oct 17;65(10):3730-3748. doi: 10.1044/2022_JSLHR-22-00262. Epub 2022 Sep 27.
The purpose of this study was to examine the respiratory strategies used by persons with Parkinson's disease (PD) to support louder speech in response to two voice interventions. Contrasting interventions were selected to investigate the role of internal and external cue strategies on treatment outcomes. LSVT LOUD, which uses an internal cueing framework, and the SpeechVive prosthesis, which employs an external noise cue to elicit louder speech, were studied.
Thirty-four persons with hypophonia secondary to idiopathic PD were assigned to one of three groups: LSVT LOUD ( = 12), SpeechVive ( = 12), or a nontreatment clinical control ( = 10). The LSVT LOUD and SpeechVive participants received 8 weeks of voice intervention. Acoustic and respiratory kinematic data were simultaneously collected at pre-, mid- and posttreatment during a monologue speech sample. Intervention outcomes included sound pressure level (SPL), utterance length, lung volume initiation, lung volume termination, and lung volume excursion.
As compared to controls, the LSVT LOUD and SpeechVive participants significantly increased SPL at mid- and posttreatment, thus confirming a positive intervention effect. Treatment-related changes in speech breathing were further identified, including significantly longer utterance lengths (syllables per breath group) at mid- and posttreatment, as compared to pretreatment. The respiratory strategies used to support louder speech varied by group. The LSVT LOUD participants terminated lung volume at significantly lower levels at mid- and posttreatment, as compared to pretreatment. This finding suggests the use of greater expiratory muscle effort by the LSVT LOUD participants to support louder speech. Participants in the SpeechVive group did not significantly alter their respiratory strategies across the intervention period. Single-subject effect sizes highlight the variability in respiratory strategies used across speakers to support louder speech.
This study provides emerging evidence to suggest that the LSVT LOUD and SpeechVive therapies elicit different respiratory adjustments in persons with PD. The study highlights the need to consider respiratory function when addressing voice targets in persons with PD.
本研究旨在探讨帕金森病(PD)患者在接受两种语音干预措施时用于支持更大声言语的呼吸策略。选择对比干预措施是为了研究内部和外部提示策略对治疗效果的作用。LSVT LOUD 采用内部提示框架,SpeechVive 假体则采用外部噪声提示来产生更大声的言语,本研究对这两种方法进行了研究。
34 名因特发性 PD 而出现低语音者被分配到三个组之一:LSVT LOUD(n=12)、SpeechVive(n=12)或非治疗临床对照组(n=10)。LSVT LOUD 和 SpeechVive 参与者接受了 8 周的语音干预。在独白言语样本中,在治疗前、中期和后期同时采集声学和呼吸运动学数据。干预效果包括声压级(SPL)、话语长度、肺容积起始、肺容积终止和肺容积移行。
与对照组相比,LSVT LOUD 和 SpeechVive 参与者在中期和后期的 SPL 显著增加,从而证实了干预的积极效果。进一步确定了与治疗相关的言语呼吸变化,包括中期和后期的话语长度(音节/呼吸组)显著增加,与治疗前相比。为了支持更大声的言语,各组使用的呼吸策略也有所不同。LSVT LOUD 参与者在中期和后期的肺容积终止水平显著低于治疗前,这表明 LSVT LOUD 参与者使用更大的呼气肌力量来支持更大声的言语。SpeechVive 组的参与者在整个干预期间并未显著改变其呼吸策略。个体受试者的效应量突出了不同的言语者在支持更大声的言语时使用的呼吸策略的变异性。
本研究提供了新的证据,表明 LSVT LOUD 和 SpeechVive 疗法在 PD 患者中引起不同的呼吸调整。该研究强调了在解决 PD 患者的语音目标时需要考虑呼吸功能。